Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT® (sunitinib) Extended Disease Free Survival After Surgical Removal

Business Wire October 10, 2016

Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® (axitinib) In Advanced Renal Cell Carcinoma (RCC)

Business Wire October 9, 2016

Stocks Hitting 52-Week Highs

Benzinga.com  October 7, 2016

Benzinga's Volume Movers

Benzinga.com  October 6, 2016

ICU Medical Inc. to Acquire the Hospira Infusion Systems Business from Pfizer Inc. for $1 Billion in Cash and Stock

GlobeNewswire October 6, 2016

Pfizer Completes Acquisition of Medivation

Business Wire September 28, 2016

Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress

Business Wire September 28, 2016

Markets In Monotone Mode Despite Post-Debate Rally

Benzinga.com  September 27, 2016

Fighting Addiction and Other Unmet Medical Needs with Cannabidiol

PR Newswire September 27, 2016

The Market In 5 Minutes: Oil, Debates And Epidiolex

Benzinga.com  September 26, 2016

A Peek Into The Markets: U.S. Stock Futures Signal Lower Start On Wall Street

Benzinga.com  September 26, 2016

Pfizer Decides Against Splitting Innovative And Essential Health, Will Remain One Company

Benzinga.com  September 26, 2016

UPDATE: Pfizer Says 2 Divisions Will Remain Separately Managed Within Single Company

Benzinga.com  September 26, 2016

Pfizer Decides Remaining One Company Best Positions Company To Maximize Future Value Creation

Business Wire September 26, 2016

Pfizer Announces Expiration of HSR Waiting Period For Proposed Acquisition of Medivation

Business Wire September 23, 2016

Pfizer Declares 30-Cent Fourth-Quarter 2016 Dividend

Business Wire September 22, 2016

More Pharma Deals In The Pipeline?

Benzinga.com  September 21, 2016

Drug Makers Stocks Under Review -- Pfizer, Merck, AbbVie, and Johnson & Johnson

PR Newswire September 21, 2016

Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts

Business Wire September 20, 2016

Pfizer Announces Positive Top-Line Results from REFLECTIONS B537-02 Study for PF-06438179 (infliximab-Pfizer) a Potential Biosimilar to Remicade® (infliximab)

Business Wire September 16, 2016